Clinical Edge Journal Scan

Cognitive function remains a concern with ADT treatment for prostate cancer


 

Key clinical point: Approximately half of the studies (16) in a systematic review showed no association between androgen deprivation therapy and reduced cognitive function in prostate cancer patients; however, 11 of the 31 studies showed a negative effect on cognitive functioning.

Major finding: A total of 18 studies used a prospective design to assess the impact of androgen deprivation therapy on cognitive function, totaling 968 individuals. Of these, 9 studies showed no significant effect of ADT on cognitive function.

Study details: The data come from a systematic review of 31 studies published up to February 2020.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Andela CD et al. Int J Urol. 2021 Jun 14. doi: 10.1111/iju.14596.

Recommended Reading

Preoperative and postoperative models predict post-resection survival in HCC
Federal Practitioner
Transarterial chemoembolization plus sorafenib significantly improves outcomes in severe HCC
Federal Practitioner
Briganti 2019 nomogram predicts lymph node invasion in prostate cancer
Federal Practitioner
Grade group 4 biopsy shows potential predictive value for prostate cancer
Federal Practitioner
MicroRNA risk model beats PSA and Gleason scores in prostate cancer prognosis
Federal Practitioner
MicroRNA risk model beats PSA and Gleason scores in prostate cancer prognosis
Federal Practitioner
Functional outcomes, not complications, impact quality of life after prostate cancer surgery
Federal Practitioner
Immune checkpoint protein predicts poor prostate cancer outcomes
Federal Practitioner
High-dose-rate brachytherapy proves effectiveness for lower risk prostate cancer
Federal Practitioner
Transgluteal CT biopsy succeeds in detecting prostate cancer lesions
Federal Practitioner